Neurologic adverse events of cancer immunotherapy

Imagem de Miniatura
Arquivos
art_BRITO_Neurologic_adverse_events_of_cancer_immunotherapy_2022.PDF (187.61 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC ARQUIVOS NEURO- PSIQUIATRIA
Autores
Citação
ARQUIVOS DE NEURO-PSIQUIATRIA, v.80, n.5, suppl.1, p.270-280, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cancer immunotherapy encompasses a wide range of treatment modalities that harness the anti-tumor effects of the immune system and have revolutionized oncological treatment in recent years, with approval for its use in more and more cancers. However, it is not without side effects. Several neurological adverse events have been recognized associated with immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T-cell therapy, the two main classes of cancer immunotherapy. With the increase in the prevalence of oncological diseases and this type of therapy, it is improbable that neurologists, oncologists, hematologists, and other healthcare professionals who deal with cancer patients will not encounter this type of neurologic complication in their practice in the following years.This article aims to review the epidemiology, clinical manifestations, diagnosis, and management of neurological complications associated with ICI and CAR T-cell therapy.
A imunoterapia contra o câncer engloba uma gama de modalidades de tratamento que aumentam os efeitos antitumorais do próprio sistema imunológico do paciente e revolucionaram o tratamento oncológico nos últimos anos, com aprovação para seu uso em cada vez mais neoplasias. No entanto, não é sem efeitos colaterais. Vários eventos adversos neurológicos foram reconhecidos associados aos inibidores de checkpoint imunológico (ICI) e à terapia de células T com receptor de antígeno quimérico (CAR-T), as duas principais classes de imunoterapia contra o câncer. Com o aumento da prevalência de doenças oncológicas e desse tipo de terapia, é improvável que neurologistas, oncologistas, hematologistas e demais profissionais de saúde que lidam com pacientes com câncer não encontrem esse tipo de complicação neurológica em sua prática nos próximos anos. Este artigo tem como objetivo revisar a epidemiologia, as manifestações clínicas, o diagnóstico e o manejo das complicações neurológicas associadas à terapia com ICI e células CAR-T
Palavras-chave
Immune Checkpoint Inhibitors, Immunotherapy, Adoptive, Drug-Related Side Effects and Adverse Reactions, Neurologic Manifestations, Neuromuscular Diseases, Inibidores de Checkpoint Imunológico, Imunoterapia Adotiva, Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos, Manifestações Neurológicas, Doenças Neuromusculares
URI
https://observatorio.fm.usp.br/handle/OPI/49458
Referências
  1. Abboud H, 2021, J NEUROL NEUROSUR PS, V92, P757, DOI 10.1136/jnnp-2020-325300
  2. Abboud H, 2021, J NEUROL NEUROSUR PS, V92, P897, DOI 10.1136/jnnp-2020-325302
  3. Alatrash G, 2013, EXPERT OPIN DRUG SAF, V12, P631, DOI 10.1517/14740338.2013.795944
  4. [Anonymous], 2017, Cancer Discov, V7, pOF1, DOI 10.1158/2159-8290.CD-NB2017-126
  5. Bruna J, 2020, J PERIPHER NERV SYST, V25, P171, DOI 10.1111/jns.12371
  6. Cuzzubbo S, 2017, EUR J CANCER, V73, P1, DOI [10.1016/j.ejca.2016.12:001, 10.1016/j.ejca.2016.12.001]
  7. Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7
  8. Dubey D, 2020, ANN NEUROL, V87, P659, DOI 10.1002/ana.25708
  9. Gaudy-Marqueste C, 2013, J IMMUNOTHER, V36, P77, DOI 10.1097/CJI.0b013e31827807dd
  10. Golnik KC, 1999, OPHTHALMOLOGY, V106, P1282, DOI 10.1016/S0161-6420(99)00709-5
  11. Graus F, 2019, NAT REV CLIN ONCOL, V16, P535, DOI 10.1038/s41571-019-0194-4
  12. Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9
  13. Guo CY, 2019, J CANCER, V10, P120, DOI 10.7150/jca.28120
  14. Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698
  15. Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225
  16. Harrison RA, 2020, CURR NEUROL NEUROSCI, V20, DOI 10.1007/s11910-020-01038-2
  17. Hay SI, 2017, LANCET, V389, pE1
  18. Hughes RAC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001446.pub5
  19. Johansen A, 2019, NEUROLOGY, V92, P663, DOI 10.1212/WNL.0000000000007235
  20. Johnsrud A, 2021, BLOOD ADV, V5, P4465, DOI [10.1182/bloodadvances.2021004716., 10.1182/bloodadvances.2021004716]
  21. Jordan B, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100317
  22. June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169
  23. Kemanetzoglou E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0742-1
  24. Kolb NA, 2018, MUSCLE NERVE, V58, P10, DOI 10.1002/mus.26070
  25. Lazaridis K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00212
  26. Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758
  27. Lesage C, 2019, J IMMUNOTHER, V42, P175, DOI 10.1097/CJI.0000000000000268
  28. Marini A, 2021, NEUROLOGY, V96, P754, DOI 10.1212/WNL.0000000000011795
  29. Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0
  30. Min L, 2015, CLIN CANCER RES, V21, P749, DOI 10.1158/1078-0432.CCR-14-2353
  31. Moreira A, 2019, EUR J CANCER, V106, P12, DOI 10.1016/j.ejca.2018.09.033
  32. Nakatani Y, 2018, CASE REP NEUROL, V10, P346, DOI 10.1159/000494078
  33. Narumi Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-3997-2
  34. National Cancer Institute, 2022, CAR T CELLS ENG PAT
  35. Neill L, 2020, PRACT NEUROL, V20, P287, DOI 10.1136/practneurol-2020-002550
  36. Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
  37. Oliveira MCB, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.538695
  38. Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]
  39. Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z
  40. Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
  41. Roth P, 2021, CANCER TREAT REV, V97, DOI 10.1016/j.ctrv.2021.102189
  42. Rubin DB, 2019, BRAIN, V142, P1334, DOI 10.1093/brain/awz053
  43. Santomasso Bianca, 2019, Am Soc Clin Oncol Educ Book, V39, P433, DOI 10.1200/EDBK_238691
  44. Santomasso Bianca D, 2020, Continuum (Minneap Minn), V26, P732, DOI 10.1212/CON.0000000000000873
  45. Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319
  46. Sato K, 2019, J NEURO-ONCOL, V145, P1, DOI 10.1007/s11060-019-03273-1
  47. Shi SY, 2020, J NEURO-ONCOL, V148, P291, DOI 10.1007/s11060-020-03514-8
  48. Shibaki R, 2019, JPN J CLIN ONCOL, V49, P793, DOI 10.1093/jjco/hyz087
  49. Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
  50. Shimada T, 2020, MULT SCLER RELAT DIS, V37, DOI 10.1016/j.msard.2019.101447
  51. Sievers S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00885
  52. Soror NN, 2021, CUREUS, V13, DOI 10.7759/cureus.13034
  53. Sznol M, 2017, CANCER TREAT REV, V58, P70, DOI 10.1016/j.ctrv.2017.06.002
  54. Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2
  55. Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2
  56. Twomey JD, 2021, AAPS J, V23, DOI 10.1208/s12248-021-00574-0
  57. Vogrig A, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000604
  58. Wu WK, 2017, J IMMUNOTHER, V40, P196, DOI 10.1097/CJI.0000000000000167
  59. Yakoub-Agha I, 2020, HAEMATOLOGICA, V105, P297, DOI 10.3324/haematol.2019.229781
  60. Yamout B, 2017, MULT SCLER RELAT DIS, V17, P234, DOI 10.1016/j.msard.2017.08.016
  61. Yoon JG, 2021, AM J ROENTGENOL, V217, P1461, DOI 10.2214/AJR.21.26091
  62. Zhou X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.620312

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03